Noncanonical Cell Death Induction by Reassortant Reovirus

Roxana M Rodríguez Stewart1,2, Vishnu Raghuram1, Jameson T L Berry1,2

  • 1Emory University, Atlanta, Georgia, USA.

Journal of Virology
|August 28, 2020
PubMed

Insights

Engineered reovirus (r2Reovirus) targets triple-negative breast cancer (TNBC) cells, inducing cell death through novel caspase pathways. Its efficacy depends on host cell genetics and viral gene interactions, paving the way for improved oncolytic virotherapy.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies, necessitating novel treatment strategies.
  • Mammalian orthoreovirus (reovirus) shows oncolytic potential and is under clinical investigation.
  • Engineered r2Reovirus exhibits enhanced infectivity and cytotoxicity against TNBC cells.

Purpose of the Study:

  • To elucidate the cell death mechanisms induced by r2Reovirus in TNBC.
  • To identify host and viral factors influencing r2Reovirus efficacy in TNBC.

Main Methods:

  • Infection of TNBC cells with engineered r2Reovirus.
  • Analysis of mitogen-activated protein kinase/extracellular signal-related kinase pathway activity.
  • Assessment of caspase-dependent and caspase-independent cell death pathways.
  • Mapping of genetic determinants of enhanced oncolysis.

Main Results:

  • r2Reovirus downregulates the MAPK/ERK pathway in TNBC cells.
  • Cell death induced by r2Reovirus is caspase-dependent but caspase 3-independent in some TNBC lineages.
  • Caspase 3-dependent cell death is observed in other TNBC lineages.
  • Enhanced oncolytic properties are linked to interactions between M2 and Lang gene segments.

Conclusions:

  • The mechanism of r2Reovirus-induced cell death in TNBC is influenced by host cell genetic composition.
  • Specific viral gene interactions (M2 and Lang) enhance r2Reovirus's oncolytic activity.
  • Understanding host-virus interactions is critical for developing effective oncolytic virotherapies for TNBC.